Presspart plasma technology improves inhaler performance
Solves problem of deposition of drug suspension on canister wall
Presspart, a division of the Heitkamp & Thumann Group, a leader in the supply of precision-formed components in metal and plastic, has launched a sub-micron plasma process for coating and treating the internal surfaces of pMDI canisters.
The Blackburn, UK-based firm says Presspart Plasma Coating and Presspart Plasma Treatment offer solutions to the problem of deposition of drug suspension on the canister wall. They can also improve drug stability performance.
Deposition of the active content of a drug formulation on canister surfaces is a long-standing problem with some MDI products. This ultimately leads to a reduction in the drug content in the formulation, resulting in the patient receiving less than the prescribed dose.
Presspart says its plasma technology can improve the surface energy performance of an MDI canister, thus reducing deposition. It can also improve the stability of some formulations where interactions with the aluminium substrate can lead to product degradation and reduced shelf life.
Julian Hemy, Presspart’s director of global sales, said: ‘Plasma-processed canisters will make a big difference to the performance and stability of drugs delivered through pMDIs.’